Holen Sie sich die Stockscreener-App
220.51
0.21%
-0.47
Vorhandelsmarkt:
220.35
-0.16
-0.07%
Schlusskurs vom Vortag:
$220.98
Offen:
$220.08
24-Stunden-Volumen:
386.21K
Relative Volume:
0.28
Marktkapitalisierung:
$6.93B
Einnahmen:
$302.00K
Nettoeinkommen (Verlust:
$-117.10M
KGV:
-19.81
EPS:
-11.13
Netto-Cashflow:
$-129.13M
1W Leistung:
+0.35%
1M Leistung:
+119.65%
6M Leistung:
+816.88%
1J Leistung:
+1,005%
1-Tages-Spanne:
$219.86
$220.69
1-Wochen-Bereich:
$219.36
$221.20
52-Wochen-Spanne:
$15.22
$221.20
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Firmenname
Cidara Therapeutics Inc
Sektor
Branche
Telefon
858-752-6170
Adresse
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Vergleichen Sie CDTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
220.51 | 6.95B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-11-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-17 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-12 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-08 | Eingeleitet | Guggenheim | Buy |
| 2024-08-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-09-22 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-07-26 | Eingeleitet | Citigroup | Buy |
| 2017-04-21 | Eingeleitet | Raymond James | Strong Buy |
| 2017-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-04-11 | Fortgesetzt | Wedbush | Outperform |
| 2017-02-22 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-22 | Hochstufung | WBB Securities | Sell → Hold |
| 2016-12-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-09-23 | Herabstufung | WBB Securities | Hold → Sell |
| 2015-10-09 | Hochstufung | WBB Securities | Sell → Hold |
| 2015-05-11 | Eingeleitet | Jefferies | Buy |
| 2015-05-11 | Eingeleitet | Leerink Partners | Outperform |
| 2015-05-11 | Eingeleitet | Needham | Buy |
| 2015-05-11 | Eingeleitet | Wedbush | Outperform |
| 2015-04-23 | Eingeleitet | WBB Securities | Sell |
Alle ansehen
Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten
Cidara Therapeutics (NASDAQ:CDTX) Sets New 1-Year HighStill a Buy? - MarketBeat
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck - Ashland Times-Gazette
Cidara Therapeutics stock hits 52-week high at 220.49 USD By Investing.com - Investing.com South Africa
Cidara Therapeutics stock hits 52-week high at 220.49 USD - Investing.com
Quadrature Capital Ltd Takes Position in Cidara Therapeutics, Inc. $CDTX - MarketBeat
How resilient is Cidara Therapeutics Inc. stock in market downturnsNew Guidance & High Accuracy Trade Signal Alerts - Newser
Merck Commits $9.2 Billion to Acquire Cidara Therapeutics - MSN
Gainers Report: How resilient is Cidara Therapeutics Inc stock in market downturns2025 Top Gainers & Expert-Curated Trade Recommendations - BỘ NỘI VỤ
The American biopharm company Merck plans to raise $8 billion through the sale of bonds - AKM.RU
Cidara Therapeutics (NASDAQ:CDTX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
How Cidara Therapeutics Inc. (20D0) stock behaves under inflation pressure - Newser
Ensign Peak Advisors Inc Takes $244,000 Position in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Will Cidara Therapeutics Inc. (20D0) stock hit Wall Street targetsEarnings Recap Report & AI Driven Stock Price Forecasts - Newser
Merck Kicks Off US Dollar Bond Sale to Help Fund Cidara Deal - Bloomberg.com
Merck seeks up to US$8 bil in US bond sale tied to Cidara deal — Bloomberg - The Edge Singapore
Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Intech Investment Management LLC Acquires Shares of 9,002 Cidara Therapeutics, Inc. $CDTX - MarketBeat
Street Watch: Why Cidara Therapeutics Inc. stock attracts high net worth investors - BỘ NỘI VỤ
3,783 Shares in Cidara Therapeutics, Inc. $CDTX Bought by Police & Firemen s Retirement System of New Jersey - MarketBeat
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer - AOL.com
Biotech Stocks To ConsiderNovember 25th - MarketBeat
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Halper Sadeh LLC Encourages AXTA, SEMR, CDTX Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
hVIVO gains validation from Cidara’s takeover; broker calls it a "glowing endorsement" - Proactive Investors
Why Cidara Therapeutics Inc. stock attracts high net worth investors2025 Biggest Moves & Entry Point Confirmation Signals - BỘ NỘI VỤ
hVIVO PLCMSD to acquire Cidara - Research Tree
hVIVO welcomes MSD’s move to acquire Cidara in $9.2 billion deal - Vox Markets
hVIVO hails $9.2 billion Cidara takeover after key trial wins - Proactive financial news
Cidara Therapeutics (CDTX): Assessing Valuation After a 137% One-Month Surge - Yahoo Finance
Top Biotech Stocks To ConsiderNovember 20th - MarketBeat
Cidara Therapeutics (CDTX) Completes Enrollment for Crucial Phas - GuruFocus
Cidara Therapeutics Meets Target Enrollment for Phase 3 Trial of Potential Flu Preventative - MarketScreener
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations - The Manila Times
Cidara Therapeutics Reaches Target Enrollment of Phase 3 - GlobeNewswire
Is Cidara Therapeutics Inc a good long term investmentStock Price Divergence & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Analysts Shift to Hold as Cidara's (CDTX) Recent Acquisition Deal Caps Upside - Finviz
Analysts Shift to Hold as Cidara’s (CDTX) Recent Acquisition Deal Caps Upside - MSN
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call Transcript - MSN
Top Biotech Stocks To Watch TodayNovember 21st - MarketBeat
10 Hottest SMID-Cap Stocks So Far In 2025 - Insider Monkey
Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Promising Biotech Stocks To ConsiderNovember 18th - MarketBeat
Promising Mid Cap Stocks To ConsiderNovember 17th - MarketBeat
(CDTX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Jefferies 25: Merck’s Cidara Buyout Could Help Meet Needs Of Increasingly Vaccine-Hesitant US - Citeline News & Insights
Merck Invests $9.2B in Cidara to Boost Breakthrough Flu Drug - BUCKSCO.Today
Can Cidara Therapeutics Inc. stock surprise with earnings upside2025 Market Sentiment & Free Safe Entry Trade Signal Reports - newser.com
Finanzdaten der Cidara Therapeutics Inc-Aktie (CDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):